Back to search
FDAFDA · Food and drugs·Recall number D-1007-2019

Docusate Sodium, 100mg softgels, packaged in 10 x 10 unit dose blister cards, For institutional use only, Mfg by: Aenova Holding GmBh, Miami, Fl 33186, NDC 63739-0478-10

Published March 27, 2019 · Recall initiated: January 16, 2019

Summary

FDA records drug Class II recall D-1007-2019, published March 27, 2019 and initiated January 16, 2019. Recalling firm: Rx Pak Division of McKesson Corporation; Status: Terminated; Reported quantity: 29,622 Blister Cards; Lot: Lot # 0119397, Exp 02/2020. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Labeling: Label mix-up: Secondary carton may be labeled as Gabapentin 300mg instead of Docusate Sodium 100mg softgel caps.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Rx Pak Division of McKesson Corporation
Distributor
Product was distributed to 5 major distributors who may have further distributed the product throughout the United States.
Lot
Lot # 0119397, Exp 02/2020
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Docusate Sodium, 100mg softgels, packaged in 10 x 10 unit dose blister cards, For institutional use only, Mfg by: Aenova Holding GmBh, Miami, Fl 33186, NDC 63739-0478-10 recalled?

Yes. FDA published recall D-1007-2019 on March 27, 2019. Reported hazard: Labeling: Label mix-up: Secondary carton may be labeled as Gabapentin 300mg instead of Docusate Sodium 100mg softgel caps.

What should I do if I have this product?

Voluntary: Firm initiated · Letter